GSK Informs Canadian Wholesalers Of Coreg, Paxil, Relafen Shortages
Executive Summary
GlaxoSmithKline is informing Canadian pharmacists and wholesalers that it will not be able to fill orders of Coreg, Paxil and Relafen until the end of the year
You may also be interested in...
GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?
GlaxoSmithKline plans to end 2006 with six product launches and six regulatory filings, CEO J.P. Garnier said during a presentation at the Bear Stearns Healthcare conference in New York Sept. 13
GSK’s Six Launches, Six Filings Slated For ’06: Sign Of R&D Strategy Payoff?
GlaxoSmithKline plans to end 2006 with six product launches and six regulatory filings, CEO J.P. Garnier said during a presentation at the Bear Stearns Healthcare conference in New York Sept. 13
GSK Signs GMP Consent Decree For Cidra Plant But Avoids Disgorgement Fee
Good manufacturing practices compliance efforts under GlaxoSmithKline's consent decree with FDA are likely to cost the company significantly less than Schering-Plough's 2002 agreement with the agency